15 results about "Gene activity" patented technology

The invention provides an ecDNA structure prediction method based on scATAC-seq, a method for identifying cells carrying ecDNA and a medium, and relates to the technical field of biological information. According to the ecDNA structure prediction method based on scATAC-seq, inconsistent readings of ecDNA breakpoint sources are extracted through comparison with a reference genome, enriched peak regions are called in sequence and converted into a graph, a breakpoint graph is combined with a Bayesian model, and accurate prediction of structural information such as ecDNA breakpoints, ecDNA regions and connection modes is achieved. The invention also provides a method for identifying cells carrying the ecDNA, and the method is used for accurately acquiring the cells carrying the ecDNA through standardization treatment, formation of a gene activity matrix and non-single-peak test on the ecDNA structure based on the scATAC-seq. According to the present invention, the ecDNA structure can be predicted, the cells carrying the ecDNA can be accurately identified, and the method can be used for the accurate analysis and research of the tumor heterogeneity, evolution and drug resistance process of the ecDNA.

The invention provides an application and a method of a pineapple zeaxanthin epoxidase AcoZEP1 gene, and belongs to the technical field of biology.The application is that the AcoZEP1 gene is inactivated or the activity of the AcoZEP1 gene is reduced, so that the content of ABA in pineapple leaves and the activity of ZEP in the pineapple leaves are reduced, and therefore pineapple leaf thorns are reduced; according to the method, a pineapple mutant for inactivating or reducing the activity of an AcoZEP1 gene is planted so as to reduce pineapple leaf thorns. By mutating the AcoZEP1 gene, the density of pineapple leaf thorns can be remarkably reduced, and the thorn-free pineapple germplasm can be cultivated by using molecular breeding technologies such as transgenosis and gene editing in the later period, so that data support and material support are provided for solving the problems of long time consumption, time consumption and labor consumption of cross breeding of the thorn-free pineapple variety in the pineapple industry; and the time required for thorn-free breeding of the pineapples is obviously shortened.

The invention discloses an inflammatory bowel disease treatment method based on intestinal flora regulatory gene CD24 expression. According to the method, expression or functions of CD24 in host intestinal epithelial cells are up-regulated, the intestinal flora structure is adjusted, and intestinal inflammation is relieved. CD24 up-regulation can be realized by transfecting a CD24 gene overexpression vector, applying a transcription factor or a small molecule agonist or enhancing the activity of an endogenous gene by utilizing a gene editing technology. The CD24 is regulated and controlled, so that the proportion of the phylum firmicalis to the phylum bacteroides can be normalized, the enrichment of short-chain fatty acid producing flora is promoted, the activation of NF-kappa B and NLRP3 inflammasomes is inhibited, and the intestinal barrier function is enhanced. The DSS induced colitis model is established by drinking a 2-5% dextran sodium sulfate solution by a mouse, and simulates the pathological characteristics of human ulcerative colitis. Intervention modes include oral administration, enema or nanoparticle targeted delivery of the CD24 agonist pharmaceutical composition. The invention provides a new strategy for the treatment of inflammatory bowel diseases, especially ulcerative colitis, and has obvious dual curative effects of anti-inflammation and flora regulation.

The method as disclosed herein utilizes a high throughput screening assay (GigaAssay) to produce a comprehensive mutation effect on gene activity (MEGA)-mutation activity profile (Map). The methods as disclosed herein can be used to assess the mutational effect for any gene, under any condition (e.g., drug treatment) with any assay in mammalian cells in culture. Thus, the methods provided herein can be utilized to discover and screen dominant negative variants, and provide a reliable solution to the problem of identifying unique pharmacologically active variants of proteins. Furthermore, the method provided herein can be integrated to cell-based assays to investigate disease pathology and test potential drugs.

The present invention provides a double-stranded RNA used to suppress the expression of mannan-binding lectin-related serine protease 2 (MASP2) in cells, cells containing the nucleotide encoding the same, and a method for treating a disease or condition mediated by or related to MASP2 expression in a subject using the dsRNA or cells.

The invention provides a method for in-vitro detection of exogenous gene expression activity of AAV virus in nerve cells and an evaluation system. The method comprises the following steps: infecting N2A cranial nerve tumor cells by using AAV carrying a neuron-specific promoter or a glial cell-specific promoter and a reporter gene driven by the neuron-specific promoter or the glial cell-specific promoter; and detecting the level of a reporter gene transcript or a protein expressed by the reporter gene in the infected N2A cranial nerve tumor cell so as to detect the activity of the AAV expressing the exogenous gene. According to the method disclosed by the invention, the target gene expression driven by the CamKII promoter of the AAV9 serotype is tested by utilizing the N2A cranial nerve tumor cells, the problem that a suitable cell model is lacked in the prior art is solved, and a new tool and a new method are provided for AAV activity test in neurobiology research.

The invention discloses a pig SINE-RIP probe combination, a gene chip, a kit and application, the pig SINE-RIP probe combination is based on a reference genome Sscrofa11.1, has wide variety and group applicability, and detects a type of SINE-RIP structure variation markers of SINE-RIP which is large in fragment, easy to cause gene activity change and large in genetic effect. The method is suitable for various applications and researches such as pig genome selective breeding, pig germplasm resource identification and evaluation, genetic relationship analysis, genetic diversity analysis and evaluation, functional gene or locus positioning, whole genome association analysis and the like, the detection process is convenient to operate, the flux is high, the cost is low, the detection rate is high, and the typing result is accurate. The probe combination effectively supplements and even substitutes an existing SNP molecular marker system, the accuracy of genome selection can be further improved, a brand-new high-reliability tool is provided for whole genome related research and application of pigs, and the industrial application value is extremely high.

Provided are a double-stranded RNA for inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a cell, a cell comprising a nucleotide encoding the same, and a method of using the dsRNA or cell to treat a disease or condition mediated or associated with the expression of MASP2 in a subject.

The invention discloses a method for increasing glutamic acid yield. Modified bacteria that produce L-glutamic acid are provided wherein a heterologous polynucleotide of phosphoketolase (XFP), and one or more of a modification of increased activity of the gluAA1T, icd gene, aceE gene and / or pyc gene, are included in the genome as compared to non-modified bacteria. In addition, methods of increasing the yield of L-glutamic acid using the modified bacteria are also provided.

The invention relates to the field of intelligent medical treatment, in particular to a multi-omics cell type annotation method and device based on deep learning and a program product. Comprising the following steps: acquiring scRNA-seq data and scATAC-seq data; the scRNA-seq data is preprocessed, and a gene expression matrix is obtained; transmitting the gene expression matrix to a first cell type classification model to obtain a first cell type prediction result; transmitting the first cell type prediction result and a gene expression matrix to a second cell type classification model to obtain a gene-type potential space; scATAC-seq data gene activity is calculated, and a feature matrix is generated; and mapping the feature matrix to a gene-type potential space to obtain a multi-omics cell type annotation result. The application has good clinical value.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of an MdPAT1 gene or a biological material containing the MdPAT1 gene in regulation and control of cold resistance of apples. Through agrobacterium-mediated transgenosis, the MdPAT1 gene is over-expressed in the GL-3 apple, and it is found that the MdPAT1 gene can significantly improve the tolerance of the apple to low temperature; the overexpressed MdPAT1 enhances the cold resistance of the apple by promoting the expression of a low-temperature response gene, an active oxygen scavenging gene and a jasmonic acid synthesis gene. On the basis, a certain application foundation can be laid for cultivation of new apple cold-resistant varieties.

The invention discloses a test method of reaction of EPHX1 genotype based COPD to NAC. The test method comprises the following steps: extracting a DNA by a phenol / chloroform method and sequencing, dividing COPD patients into slow and very slow gene activity group and a quick and normal gene activity group according to EPHX1 gene polymorphism, giving 600 mg Bid of NAC for 1 year to both groups, performing baseline measurement of pulmonary function parameters, completing SGRQ and 6MWT, measuring FVC and FEV1 at a follow-up day every 12 weeks, completingSGRQ and 6MWT in 24 and 48 weeks, and recording the number of acute exacerbationof COPD in one year. The data were statistically analyzed with SPSS. The results show that NAC is effective in the treatment of slow and very slow EPHX1 gene activityCOPD patients. The test method provided by the invention provides a solid basis for demonstrating the effect and mechanism of NAC based on pharmacogenomics in the individualized treatment of COPD.

The present invention relates to a novel in vivo expression system for biocontainment and gene expression control in microbes including modified and / or unmodified for application in processes of altering cell multiplication, activating cell lysis, altering metabolism and product formation, etc. The said gene expression control system can be switched on (activated) and off (deactivated) depending on presence and absence of externally and / or internally active inducer or product of gene activity, etc. The said biocontainment and gene expression control system are useful for in vitro applications (production in Bioreactors) and also for in situ applications including but not limited to application on plant, soil, water treatment, aquaculture, cattle feed, gut applications, etc.

This invention discloses a KDM4C inhibitor and its applications, relating to the field of biomedical technology. Specifically, this invention discloses the application of the KDM4C inhibitor in any of A1) to A5): A1) preparing a drug for the prevention or treatment of obesity; A2) preparing a drug for reducing weight; A3) preparing a drug for reducing food intake; A4) preparing a drug for reducing insulin sensitivity; A5) preparing a drug for enhancing glucose homeostasis. This is achieved through knockout... Kdm4c Inhibiting KDM4C gene activity or inhibiting KDM4C activity can significantly reduce obesity induced by a high-fat diet, thereby regulating the secretion of related hormones / adipokines, affecting food intake, improving insulin resistance, and enhancing insulin sensitivity, making it a potential target for the treatment of obesity.

The invention particularly relates to an efficient integration method for single-cell multi-omics matching data. The method comprises the following steps: acquiring the single-cell multi-omics matching data; wherein the single-cell multi-omics matching data comprises matched transcriptome data scRNA-seq and chromatin accessibility data scATAC-seq, and the single-cell multi-omics matching data comprises the transcriptome data scRNA-seq and the chromatin Converting peak data of the chromatin accessibility data into a gene activity matrix; performing low-quality filtering on the single-cell multi-omics matching data, deleting abnormal cells, and preprocessing a gene expression matrix of transcriptome data and a gene activity matrix of chromatin accessibility data; respectively constructing a first graph structure and a second graph structure for a gene expression matrix of the preprocessed transcriptome data and a gene activity matrix of the preprocessed chromatin accessibility data; constructing an integrated model of transcriptome and chromatin accessibility; and inputting the first graph structure and the second graph structure into an integration model for training to obtain integrated data. According to the method, biological characteristics are reserved to the maximum extent, the calculation scale is reduced, and the accurate and efficient multi-omics data integration method is achieved.